Humanigen Announces Target Enrollment In Phase 2/3 ACTIV-5/BET-B Trial Of Lenzilumab For The Treatment Of COVID-19 Has Been Achieved

Published by
The Street

By Business Wire Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’, announced that target enrollment in the Phase 2/3 ACTIV-5/BET-B study has been achieved. The study, sponsored by the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, enrolled over 400 patients in the primary analysis population at approximately 55 recruiting clinical sites including international sites. The ACTIV-5/BET-B study was designed to align with the …

Read More